Who we are

After nearly 20 years of research and teaching as a faculty member at the University of Kansas and the University of Minnesota, Dr. Sunil David founded ViroVax, LLC in 2019 in Lawrence, KS.  ViroVax is a biotechnology company focused on research and development of vaccines, adjuvants, and therapeutics to protect and treat people from infectious diseases, including Zika, West Nile, Dengue, and SARS-CoV-2.

Dr. David received his training from the Christian Medical College in Vellore, India. Following postdoctoral training stints at the Forschungszentrum, Borstel, Germany, the Indian Institute of Science, Bangalore, and the University of Kansas Medical Center, he joined the faculty at KU before being recruited by the Department of Medicinal Chemistry at the University of Minnesota. His research focuses on the modulation of innate immune pathways, host responses to infectious agents, vaccine adjuvants, and subunit vaccines.